Company: SMNR
Filing Date: 2025-08-15
Form Type: 10-Q
Source: 0001213900-25-077047
Chunk: 1

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-15
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 shares, $0.0001 par value; 200,000,000 shares authorized, 510,000 shares issued and outstanding (excluding 43,739 and 751,837 shares subject to possible redemption as of June 30, 2025 and December 31, 2024, respectively subject to possible redemption) 
     51  
     51 
  
    Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized, 2,062,500 shares issued and outstanding as of June 30, 2025 and December 31, 2024 
     206  
     206 
  
    Accumulated deficit 
     (11,142,564) 
     (10,417,973)
  
    Total shareholders’ deficit 
     (11,142,307) 
     (10,417,716)
  
    Total Liabilities and Shareholders’ Deficit 
    $562,462  
    $9,037,873 

The accompanying notes are an integral part of these unaudited
condensed financial statements.

1

DENALI CAPITAL ACQUISITION CORP.

CONDENSED CONSOLDATED STATEMENTS OF
OPERATIONS

(Unaudited)

    For the  
    For the  
    For the  
    For the 

    Three Months Ended  
    Three Months Ended  
    Six  Months Ended  
    Six  Months Ended 

    June 30, 2025  
    June 30, 2024  
    June 30, 2025  
    June 30, 2024 

    Formation and operating costs 
    $374,857  
    $168,186  
    $621,457  
    $536,438 
  
    Loss from operations 
     374,857  
     168,186  
     621,457  
     536,438 

    Other expense/(income) 

    Interest expense 
     28,345  
     23,059  
     55,319  
     44,362 
  
    Income on Trust account 
     (18,080) 
     (640,157) 
     (97,051) 
     (1,294,042)

    Net (loss)/ income 
    $(385,122)